Proteins and Peptides
26 March 2014
GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan® (albiglutide)25 March 2014
Halozyme Announces Positive Results From Phase 1/2 Clinical Trial In Cellulite With HTI-50124 March 2014
Kamada Announces Initiation of a Phase 2 U.S. Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency19 March 2014
Emmaus Life Sciences Announces Positive Top-Line Results Of Its Phase 3 Clinical Trial For Sickle Cell Disease27 February 2014
European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company’s Oritavancin25 February 2014
FDA approves Myalept to treat rare metabolic disease24 February 2014
Palatin Technologies Presents Positive New Data Analyses Demonstrating Efficacy of Bremelanotide in Female Hypoactive Sexual Desire Disorder20 February 2014
BioMarin Receives Positive Opinion From the CHMP in the European Union for VIMIZIM(TM) (elosulfase alfa) for Morquio A Syndrome19 February 2014
FDA Accepts Filing of the Medicines Company’s New Drug Application for Intravenous Antibiotic Oritavancin With Priority Review18 February 2014
Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease18 February 2014
Bayer ’s Long-Acting Recombinant Factor VIII Demonstrated Effective Prophylaxis with Less Frequent Infusions in Hemophilia A in Phase III TrialNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports